These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27175500)

  • 1. [Investigation of fluoroquinolone resistance mechanisms in clinical Acinetobacter baumannii isolates].
    Güler G; Eraç B
    Mikrobiyol Bul; 2016 Apr; 50(2):278-86. PubMed ID: 27175500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.
    Sun C; Hao J; Dou M; Gong Y
    J Antibiot (Tokyo); 2015 May; 68(5):313-7. PubMed ID: 25351948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insertion sequence disruption of adeR and ciprofloxacin resistance caused by efflux pumps and gyrA and parC mutations in Acinetobacter baumannii.
    Lopes BS; Amyes SG
    Int J Antimicrob Agents; 2013 Feb; 41(2):117-21. PubMed ID: 23217848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Investigation of the virulence factors of multidrug-resistant Acinetobacter baumannii isolates].
    Eraç B; Yılmaz FF; Hoşgör Limoncu M; Oztürk I; Aydemir S
    Mikrobiyol Bul; 2014 Jan; 48(1):70-81. PubMed ID: 24506717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    J Antimicrob Chemother; 2004 Oct; 54(4):821-3. PubMed ID: 15355942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California.
    Valentine SC; Contreras D; Tan S; Real LJ; Chu S; Xu HH
    J Clin Microbiol; 2008 Aug; 46(8):2499-507. PubMed ID: 18524965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-existence of blaOXA-23 and armA in multidrug-resistant Acinetobacter baumannii isolated from a hospital in South Korea.
    Hong SB; Shin KS; Ha J; Han K
    J Med Microbiol; 2013 Jun; 62(Pt 6):836-844. PubMed ID: 23518656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones.
    Mohammed MA; Ahmed MT; Anwer BE; Aboshanab KM; Aboulwafa MM
    PLoS One; 2020; 15(8):e0238195. PubMed ID: 32845920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular characterization of beta-lactamase-associated resistance in Acinetobacter baumannii strains isolated from clinical samples].
    Keskin H; Tekeli A; Dolapci İ; Öcal D
    Mikrobiyol Bul; 2014 Jul; 48(3):365-76. PubMed ID: 25052103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU.
    Liu YH; Kuo SC; Lee YT; Chang IC; Yang SP; Chen TL; Fung CP
    J Microbiol Immunol Infect; 2012 Apr; 45(2):108-12. PubMed ID: 22153765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in Acinetobacter baumannii clinical isolates in Taiwan.
    Chiu CH; Lee HY; Tseng LY; Chen CL; Chia JH; Su LH; Liu SY
    Int J Antimicrob Agents; 2010 Apr; 35(4):382-6. PubMed ID: 20138741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii.
    Wisplinghoff H; Decker M; Haefs C; Krut O; Plum G; Seifert H
    J Antimicrob Chemother; 2003 Jan; 51(1):177-80. PubMed ID: 12493807
    [No Abstract]   [Full Text] [Related]  

  • 14. Characteristics of antibiotic resistance and sequence type of Acinetobacter baumannii clinical isolates in Japan and the antibacterial activity of DS-8587.
    Higuchi S; Shikata M; Chiba M; Hoshino K; Gotoh N
    J Infect Chemother; 2014 Apr; 20(4):256-61. PubMed ID: 24709045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the gyrA and parC genes in ciprofloxacin-resistant clinical isolates of Acinetobacter baumannii in Korea.
    Lee JK; Lee YS; Park YK; Kim BS
    Microbiol Immunol; 2005; 49(7):647-53. PubMed ID: 16034208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
    Higgins PG; Stubbings W; Wisplinghoff H; Seifert H
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1613-5. PubMed ID: 20100879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of ciprofloxacin resistance with the AdeABC efflux system in Acinetobacter baumannii clinical isolates.
    Ardebili A; Lari AR; Talebi M
    Ann Lab Med; 2014 Nov; 34(6):433-8. PubMed ID: 25368818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-drug resistance profiles and the genetic features of Acinetobacter baumannii isolates from Bolivia.
    Lopes BS; Gallego L; Amyes SG
    J Infect Dev Ctries; 2013 Apr; 7(4):323-8. PubMed ID: 23592642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
    Zhang FF; Zhao CJ; Wang H
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acinetobacter baumannii isolates from pets and horses in Switzerland: molecular characterization and clinical data.
    Endimiani A; Hujer KM; Hujer AM; Bertschy I; Rossano A; Koch C; Gerber V; Francey T; Bonomo RA; Perreten V
    J Antimicrob Chemother; 2011 Oct; 66(10):2248-54. PubMed ID: 21733964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.